CURE.DE vs. ETLI.DE
CURE.DE (VanEck Genomics and Healthcare Innovators UCITS ETF A) and ETLI.DE (L&G Pharma Breakthrough UCITS ETF) are both Health & Biotech Equities funds - CURE.DE tracks the MVIS Global Future Healthcare ESG while ETLI.DE tracks the Solactive Pharma Breakthrough Value. Both are passively managed. Over the past 3 years, CURE.DE returned -2.48%/yr vs 2.83%/yr for ETLI.DE. A 0.71 correlation means they provide meaningful diversification when combined. CURE.DE charges 0.35%/yr vs 0.49%/yr for ETLI.DE.
Performance
CURE.DE vs. ETLI.DE - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, CURE.DE achieves a -5.10% return, which is significantly lower than ETLI.DE's -0.74% return.
CURE.DE
- 1D
- 4.01%
- 1M
- 6.73%
- YTD
- -5.10%
- 6M
- -8.62%
- 1Y
- 6.04%
- 3Y*
- -2.48%
- 5Y*
- —
- 10Y*
- —
ETLI.DE
- 1D
- 2.62%
- 1M
- -4.04%
- YTD
- -0.74%
- 6M
- -2.52%
- 1Y
- 22.46%
- 3Y*
- 2.83%
- 5Y*
- 2.31%
- 10Y*
- —
CURE.DE vs. ETLI.DE - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
CURE.DE VanEck Genomics and Healthcare Innovators UCITS ETF A | -5.10% | 5.09% | 0.30% | -6.42% | -4.35% |
ETLI.DE L&G Pharma Breakthrough UCITS ETF | -0.74% | 22.23% | 0.42% | -12.64% | 1.47% |
Correlation
The correlation between CURE.DE and ETLI.DE is 0.72, which is moderate. They share some common price drivers but move independently often enough to provide real diversification benefit when combined.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.72 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.71 |
Correlation (All Time) Calculated using the full available price history since Sep 8, 2022 | 0.71 |
The correlation between CURE.DE and ETLI.DE has been stable across timeframes, ranging from 0.71 to 0.72 - a consistent structural relationship.
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
CURE.DE vs. ETLI.DE — Risk / Return Rank
CURE.DE
ETLI.DE
CURE.DE vs. ETLI.DE - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for VanEck Genomics and Healthcare Innovators UCITS ETF A (CURE.DE) and L&G Pharma Breakthrough UCITS ETF (ETLI.DE). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| CURE.DE | ETLI.DE | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.87 | ||
| Sortino ratioReturn per unit of downside risk | -1.20 | ||
| Omega ratioGain probability vs. loss probability | 1.06 | 1.20 | -0.14 |
| Calmar ratioReturn relative to maximum drawdown | 0.30 | 2.40 | -2.10 |
| Martin ratioReturn relative to average drawdown | 0.68 | 6.79 | -6.11 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| CURE.DE | ETLI.DE | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 0.29 | 1.16 | -0.87 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | — | 0.13 | — |
Sharpe Ratio (All Time)Calculated using the full available price history | -0.14 | 0.22 | -0.36 |
Drawdowns
CURE.DE vs. ETLI.DE - Drawdown Comparison
The maximum CURE.DE drawdown since its inception was -34.80%, which is greater than ETLI.DE's maximum drawdown of -30.83%. Use the drawdown chart below to compare losses from any high point for CURE.DE and ETLI.DE.
Loading charts...
Drawdown Indicators
| CURE.DE | ETLI.DE | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -34.80% | -30.83% | -3.97% |
Max Drawdown (1Y)Largest decline over 1 year | -19.07% | -9.06% | -10.01% |
Max Drawdown (3Y)Largest decline over 3 years | -29.32% | -23.90% | -5.42% |
Max Drawdown (5Y)Largest decline over 5 years | — | -30.83% | — |
Current DrawdownCurrent decline from peak | -15.66% | -4.86% | -10.80% |
Average DrawdownAverage peak-to-trough decline | -15.12% | -10.22% | -4.90% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 8.53% | 3.21% | +5.32% |
Volatility
CURE.DE vs. ETLI.DE - Volatility Comparison
The current volatility for VanEck Genomics and Healthcare Innovators UCITS ETF A (CURE.DE) is 5.73%, while L&G Pharma Breakthrough UCITS ETF (ETLI.DE) has a volatility of 6.89%. This indicates that CURE.DE experiences smaller price fluctuations and is considered to be less risky than ETLI.DE based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| CURE.DE | ETLI.DE | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 5.73% | 6.89% | -1.16% |
Volatility (6M)Calculated over the trailing 6-month period | 15.20% | 14.09% | +1.11% |
Volatility (1Y)Calculated over the trailing 1-year period | 19.97% | 18.72% | +1.25% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 20.74% | 17.22% | +3.52% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 20.74% | 18.91% | +1.83% |
CURE.DE vs. ETLI.DE - Expense Ratio Comparison
CURE.DE has a 0.35% expense ratio, which is lower than ETLI.DE's 0.49% expense ratio.
Dividends
CURE.DE vs. ETLI.DE - Dividend Comparison
Neither CURE.DE nor ETLI.DE has paid dividends to shareholders.
Frequently Asked Questions
CURE.DE and ETLI.DE have a correlation of 0.72, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
On fees, CURE.DE is cheaper at 0.35% per year. The better choice depends on whether you care most about return, fees, risk, or income.
CURE.DE is cheaper with a 0.35% expense ratio, compared with 0.49% for ETLI.DE.
CURE.DE tracks MVIS Global Future Healthcare ESG, while ETLI.DE tracks Solactive Pharma Breakthrough Value. They also come from different issuers: VanEck and Legal & General. Their fees differ too: 0.35% for CURE.DE and 0.49% for ETLI.DE.
Find the right allocation for CURE.DE and ETLI.DE
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer